Massive parallel sequencing in sarcoma pathobiology: State of the art and perspectives

Monica Brenca, Roberta Maestro

Research output: Contribution to journalArticlepeer-review


Sarcomas are an aggressive and highly heterogeneous group of mesenchymal malignancies with different morphologies and clinical behavior. Current therapeutic strategies remain unsatisfactory. Cytogenetic and molecular characterization of these tumors is resulting in the breakdown of the classical histopathological categories into molecular subgroups that better define sarcoma pathobiology and pave the way to more precise diagnostic criteria and novel therapeutic opportunities.The purpose of this short review is to summarize the state-of-the-art on the exploitation of massive parallel sequencing technologies, also known as next generation sequencing, in the elucidation of sarcoma pathobiology and to discuss how these applications may impact on diagnosis, prognosis and therapy of these tumors.

Original languageEnglish
Pages (from-to)1473-1488
Number of pages16
JournalExpert Review of Anticancer Therapy
Issue number12
Publication statusPublished - Dec 2 2015


  • diagnosis
  • fusion gene
  • massive parallel sequencing
  • next generation sequencing
  • pathobiology
  • prognosis
  • sarcoma
  • therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Massive parallel sequencing in sarcoma pathobiology: State of the art and perspectives'. Together they form a unique fingerprint.

Cite this